A comprehensive update of siRNA delivery design strategies for targeted and effective gene silencing in gene therapy and other applications

References

• Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004;431(7006):343–349.
   PubMed Web of Science ®Google Scholar
• Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 2010;28(11):570–579.
   PubMed Web of Science ®Google Scholar
• ONPATTRO full prescribing information by FDA. 2018. [cited 10 January 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf
   Google Scholar
• GIVLAARI full prescribing informations by FDA. 2019. [cited 12 January 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0212194s000lbl.pdf
   Google Scholar
• OXLUMO full prescribing informations by FDA. 2020. [cited 12 January 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214103lbl.pdf
   Google Scholar
• LEQVIO® (inclisiran) full prescribing information by FDA. 2021. [cited 15 May 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf
   Google Scholar
• Zhang MM, Bahal R, Rasmussen TP, et al. The growth of siRNA-based therapeutics: updated clinical studies. Biochem Pharmacol. 2021;189:114432.
   PubMed Web of Science ®Google Scholar
• Harvey C, Klassa S, Finol E, et al. Chimeric flaviviral RNA− siRNA molecules resist degradation by the exoribonuclease Xrn1 and trigger gene silencing in mammalian cells. ChemBioChem. 2021;22(21):3099–3106.
   PubMed Web of Science ®Google Scholar
• Li WM, Barnes T, Lee CH. Endoribonucleases–enzymes gaining spotlight in mRNA metabolism. FEBS J. 2010;277(3):627–641.
   PubMed Web of Science ®Google Scholar
• Bartlett DW, Davis ME. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA‐mediated gene silencing. Biotechnol Bioeng. 2007;97(4):909–921.
   PubMed Web of Science ®Google Scholar
• Gao S, Dagnaes-Hansen F, Nielsen EJB, et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther. 2009;17(7):1225–1233.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim A, Miyata K, et al. Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv Drug Deliv Rev. 2016;104:61–77.
   PubMed Web of Science ®Google Scholar
• Shegokar R, Al Shaal L, Mishra P. SiRNA delivery: challenges and role of carrier systems. Die Pharmazie- Int J Pharm Sci. 2011;66(5):313–318.
   Google Scholar
• Tai W. Current aspects of siRNA bioconjugate for in vitro and in vivo delivery. Molecules. 2019;24(12):2211.
   PubMed Web of Science ®Google Scholar
• Watts JK, Deleavey GF, Damha MJ. Chemically modified siRNA: tools and applications. Drug Discov Today. 2008;13(19–20):842–855.
   PubMed Web of Science ®Google Scholar
• Chiu Y-L, Rana TM. siRNA function in RNAi: a chemical modification analysis. Rna. 2003;9(9):1034–1048.
   PubMed Web of Science ®Google Scholar
• Bardoliwala D, Patel V, Javia A, et al. Nanocarriers in effective pulmonary delivery of siRNA: current approaches and challenges. Ther Deliv. 2019;10(5):311–332.
   PubMed Web of Science ®Google Scholar
• Alshaer W, Zureigat H, Al Karaki A, et al. siRNA: mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol. 2021;916:174178.
   Web of Science ®Google Scholar
• Okamura K, Ishizuka A, Siomi H, et al. Distinct roles for Argonaute proteins in small RNA-directed RNA cleavage pathways. Genes Dev. 2004;18(14):1655–1666.
   PubMed Web of Science ®Google Scholar
• Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):1–25.
   PubMed Web of Science ®Google Scholar
• Caillaud M, El Madani M, Massaad-Massade L. Small interfering RNA from the lab discovery to patients’ recovery. J Control Release. 2020;321:616–628.
   PubMed Web of Science ®Google Scholar
• Juliano R, Bauman J, Kang H, et al. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm. 2009;6(3):686–695.
   PubMed Web of Science ®Google Scholar
• S-D L, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochimi Biophys Acta (BBA) Biomembr. 2009;1788(10):2259–2266.
   PubMed Web of Science ®Google Scholar
• Wang J, Lu Z, Wientjes MG, et al. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010;12(4):492–503.
   PubMed Web of Science ®Google Scholar
• Sato Y, Hatakeyama H, Hyodo M, et al. Relationship between the physicochemical properties of lipid nanoparticles and the quality of siRNA delivery to liver cells. Mol Ther. 2016;24(4):788–795.
   PubMed Web of Science ®Google Scholar
• C-f X, Wang J. Delivery systems for siRNA drug development in cancer therapy. Asian J Pharm Sci. 2015;10(1):1–12.
   Web of Science ®Google Scholar
• Lam JK, Chow MY, Zhang Y, et al. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4:e252.
   PubMedGoogle Scholar
• Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med. 2012;85(2):187.
   PubMedGoogle Scholar
• Elbashir SM, Martinez J, Patkaniowska A, et al. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 2001;20(23):6877–6888.
   PubMed Web of Science ®Google Scholar
• Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003;31(11):2705–2716.
   PubMed Web of Science ®Google Scholar
• Deleavey GF, Damha MJ. Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol. 2012;19(8):937–954.
   PubMed Web of Science ®Google Scholar
• Mutisya D, Hardcastle T, Cheruiyot SK, et al. Amide linkages mimic phosphates in RNA interactions with proteins and are well tolerated in the guide strand of short interfering RNAs. Nucleic Acids Res. 2017;45(14):8142–8155.
   PubMed Web of Science ®Google Scholar
• Sarisozen C, Salzano G, Torchilin P. Lipid-based siRNA delivery systems: challenges, promises and solutions along the long journey. Curr Pharm Biotechnol. 2016;17(8):728–740.
   PubMed Web of Science ®Google Scholar
• Jayasena SD, Reynolds A, Khvorova A. Functional siRNAs and miRNAs Exhibit Strand Bias. Cell. 2003;115(4):505.
   Web of Science ®Google Scholar
• Schwarz DS, Hutvágner G, Du T, et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell. 2003;115(2):199–208.
   PubMed Web of Science ®Google Scholar
• Sipa K, Sochacka E, Kazmierczak-Baranska J, et al. Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. Rna. 2007;13(8):1301–1316.
   PubMed Web of Science ®Google Scholar
• Gaglione M, Messere A. Recent progress in chemically modified siRNAs. Mini Rev Med Chem. 2010;10(7):578–595.
   PubMed Web of Science ®Google Scholar
• Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell. 2003;115(2):209–216.
   PubMed Web of Science ®Google Scholar
• Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017;35(3):238–248.
   PubMed Web of Science ®Google Scholar
• McNamara JO, Andrechek ER, Wang Y, et al. Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 2006;24(8):1005–1015.
   PubMed Web of Science ®Google Scholar
• Kubo T, Nishimura Y, Hatori Y, et al. Antitumor effect of palmitic acid‐conjugated Dsi RNA for colon cancer in a mouse subcutaneous tumor model. Chem Biol Drug Des. 2019;93(4):570–581.
   PubMed Web of Science ®Google Scholar
• Foster DJ, Brown CR, Shaikh S, et al. Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol Ther. 2018;26(3):708–717.
   PubMed Web of Science ®Google Scholar
• Bäumer S, Bäumer N, Appel N, et al. Antibody-mediated delivery of anti–KRAS-siRNA in vivo overcomes therapy resistance in colon cancer. Clin Cancer Res. 2015;21(6):1383–1394.
   PubMed Web of Science ®Google Scholar
• Song E, Zhu P, Lee S-K, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23(6):709–717.
   PubMed Web of Science ®Google Scholar
• Kumar P, Ban H-S, Kim -S-S, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell. 2008;134(4):577–586.
   PubMed Web of Science ®Google Scholar
• Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063–7070.
   PubMed Web of Science ®Google Scholar
• Nair JK, Willoughby JL, Chan A, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136(49):16958–16961.
   PubMed Web of Science ®Google Scholar
• Wong SC, Klein JJ, Hamilton HL, et al. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther. 2012;22(6):380–390.
   PubMed Web of Science ®Google Scholar
• Sugo T, Terada M, Oikawa T, et al. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J Control Release. 2016;237:1–13.
   PubMed Web of Science ®Google Scholar
• Yu Z, Zhang X, Pei X, et al. Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA. Int J Pharm. 2021;606:120940.
   PubMed Web of Science ®Google Scholar
• Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146(3):264–275.
   PubMed Web of Science ®Google Scholar
• Parry JJ, Kelly TS, Andrews R, et al. In vitro and in vivo evaluation of 64Cu-labeled DOTA− linker− bombesin (7− 14) analogues containing different amino acid linker moieties. Bioconjug Chem. 2007;18(4):1110–1117.
   PubMed Web of Science ®Google Scholar
• Tai W, Shukla RS, Qin B, et al. Development of a peptide–drug conjugate for prostate cancer therapy. Mol Pharm. 2011;8(3):901–912.
   PubMed Web of Science ®Google Scholar
• Tai W, Gao X. Functional peptides for siRNA delivery. Adv Drug Deliv Rev. 2017;110:157–168.
   PubMed Web of Science ®Google Scholar
• Gandioso A, Massaguer A, Villegas N, et al. Efficient siRNA–peptide conjugation for specific targeted delivery into tumor cells. Chem Comm. 2017;53(19):2870–2873.
   PubMed Web of Science ®Google Scholar
• Luo J, Höhn M, Reinhard S, et al. IL4‐Receptor‐Targeted Dual Antitumoral Apoptotic Peptide—siRNA conjugate lipoplexes. Adv Funct Mater. 2019;29(25):1900697.
   Web of Science ®Google Scholar
• Eyford BA, Singh CS, Abraham T, et al. A nanomule peptide carrier delivers siRNA across the intact blood-brain barrier to attenuate ischemic stroke. Front Mol Biosci. 2021;8:133.
   Web of Science ®Google Scholar
• Srimanee A, Arvanitidou M, Kim K, et al. Cell-penetrating peptides for siRNA delivery to glioblastomas. Peptides. 2018;104:62–69.
   PubMed Web of Science ®Google Scholar
• Moschos SA, Jones SW, Perry MM, et al. Lung delivery studies using siRNA conjugated to TAT (48− 60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem. 2007;18(5):1450–1459.
   PubMed Web of Science ®Google Scholar
• Olson ES, Aguilera TA, Jiang T, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol. 2009;1(5–6):382–393.
   Google Scholar
• Shi N-Q, Gao W, Xiang B, et al. Enhancing cellular uptake of activable cell-penetrating peptide–doxorubicin conjugate by enzymatic cleavage. Int J Nanomedicine. 2012;7:1613.
   PubMed Web of Science ®Google Scholar
• Martín I, Teixidó M, Giralt E. Building cell selectivity into CPP-mediated strategies. Pharmaceuticals. 2010;3(5):1456–1490.
   Google Scholar
• Zhou J, Rossi J. Cell-type–specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy. J Invest Med. 2014;62(7):914–919.
   PubMed Web of Science ®Google Scholar
• Kruspe S, Giangrande PH. Aptamer-siRNA chimeras: discovery, progress, and future prospects. Biomedicines. 2017;5(3):45.
   PubMed Web of Science ®Google Scholar
• Khanali J, Azangou-khyavy M, Asaadi Y, Jamalkhah, M, Kiani, J, et al. Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs. Front Microbiol. 2021;12:758948.
   PubMedGoogle Scholar
• Xia C-F, Boado RJ, Pardridge WM. Antibody-mediated targeting of siRNA via the human insulin receptor using avidin− biotin technology. Mol Pharm. 2009;6(3):747–751.
   PubMedGoogle Scholar
• Ma Y, Kowolik CM, Swiderski PM, et al. Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA. ACS Chem Biol. 2011;6(9):962–970.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Convertine AJ, Cutler-Strom R, et al. Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells. Mol Ther. 2011;19(8):1529–1537.
   PubMed Web of Science ®Google Scholar
• Alam MR, Ming X, Fisher M, et al. Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. Bioconjug Chem. 2011;22(8):1673–1681.
   PubMed Web of Science ®Google Scholar
• Blackburn WH, Dickerson EB, Smith MH, et al. Peptide-functionalized nanogels for targeted siRNA delivery. Bioconjug Chem. 2009;20(5):960–968.
   PubMed Web of Science ®Google Scholar
• Cesarone G, Edupuganti OP, Chen C-P, et al. Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1. Bioconjug Chem. 2007;18(6):1831–1840.
   PubMed Web of Science ®Google Scholar
• Jafari R, Zolbanin NM, Majidi J, et al. Anti-mucin1 aptamer-conjugated chitosan nanoparticles for targeted co-delivery of docetaxel and IGF-1R siRNA to SKBR3 metastatic breast cancer cells. Iran Biomed J. 2019;23(1):21.
   PubMedGoogle Scholar
• Xu Y, Pang L, Wang H, et al. Specific delivery of delta-5-desaturase siRNA via RNA nanoparticles supplemented with dihomo-γ-linolenic acid for colon cancer suppression. Redox Biol. 2019;21:101085.
   PubMed Web of Science ®Google Scholar
• Powell D, Chandra S, Dodson K, et al. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. Eur J Pharm Biopharm. 2017;114:108–118.
   PubMed Web of Science ®Google Scholar
• Subhan MA, Attia SA, Torchilin VP. Advances in siRNA delivery strategies for the treatment of MDR cancer. Life Sci. 2021;274:119337.
   PubMed Web of Science ®Google Scholar
• Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173–178.
   PubMed Web of Science ®Google Scholar
• Chernikov I, Meschaninova M, Venyaminova A, et al. Cholesterol-conjugated siRNA accumulates in the different hematopoietic and lymphoid cells. J Hematol Oncol Res. 2016;2(2):13–19.
   Google Scholar
• Osborn MF, Coles AH, Biscans A, et al. Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways. Nucleic Acids Res. 2019;47(3):1070–1081.
   PubMed Web of Science ®Google Scholar
• Aviñó A, Ocampo SM, Lucas R, et al. Synthesis and in vitro inhibition properties of siRNA conjugates carrying glucose and galactose with different presentations. Mol Divers. 2011;15(3):751–757.
   PubMed Web of Science ®Google Scholar
• Zhu L, Mahato RI. Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation. Bioconjug Chem. 2010;21(11):2119–2127.
   PubMed Web of Science ®Google Scholar
• Oishi M, Nagasaki Y, Itaka K, et al. Lactosylated poly (ethylene glycol)-siRNA conjugate through acid-labile β-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J Am Chem Soc. 2005;127(6):1624–1625.
   PubMed Web of Science ®Google Scholar
• Rozema DB, Lewis DL, Wakefield DH, et al., Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Nat Acad Sci. 2007. 104(32): 12982–12987.
   PubMed Web of Science ®Google Scholar
• Bayda S, Adeel M, Tuccinardi T, et al. The history of nanoscience and nanotechnology: from chemical–physical applications to nanomedicine. Molecules. 2020;25(1):112.
   Web of Science ®Google Scholar
• Zayed A, Haggag Y, Ezzat SM, et al. Fucoidans as nanoparticles: pharmaceutical and biomedical applications. Polysaccharide Nanopart. 2022;16;413–455.
   Google Scholar
• Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):1–33.
   PubMed Web of Science ®Google Scholar
• De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3(2):133.
   PubMed Web of Science ®Google Scholar
• Haggag YA, Yasser M, Tambuwala MM, et al. Repurposing of Guanabenz acetate by encapsulation into long-circulating nanopolymersomes for treatment of triple-negative breast cancer. Int J Pharm. 2021;600:120532.
   PubMed Web of Science ®Google Scholar
• Salem MA, Manaa EG, Osama N, et al. Coriander (Coriandrum sativum L.) essential oil and oil-loaded nano-formulations as an anti-aging potentiality via TGFβ/SMAD pathway. Sci Rep. 2022;12(1):1–15.
   PubMed Web of Science ®Google Scholar
• Ibrahim WM, AlOmrani AH, Yassin AEB. Novel sulpiride-loaded solid lipid nanoparticles with enhanced intestinal permeability. Int J Nanomedicine. 2014;9:129.
   PubMed Web of Science ®Google Scholar
• Zewail MB, El-Gizawy SA, Osman MA, et al. Preparation and In vitro characterization of a novel self-nano emulsifying drug delivery system for a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide. J Drug Delivery Sci Technol. 2021;61:102320.
   Web of Science ®Google Scholar
• Haggag YA, Abosalha AK, Tambuwala MM, et al. Polymeric nanoencapsulation of zaleplon into PLGA nanoparticles for enhanced pharmacokinetics and pharmacological activity. Biopharm Drug Dispos. 2021;42(1):12–23.
   PubMed Web of Science ®Google Scholar
• Fam SY, Chee CF, Yong CY, et al. Stealth coating of nanoparticles in drug-delivery systems. Nanomaterials. 2020;10(4):787.
   Web of Science ®Google Scholar
• S-D L, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5(4):496–504.
   PubMedGoogle Scholar
• Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25(10):1165–1170.
   PubMed Web of Science ®Google Scholar
• Musumeci T, Ventura CA, Giannone I, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. 2006;325(1–2):172–179.
   PubMedGoogle Scholar
• Schleifman EB, McNeer NA, Jackson A, et al. Site-specific genome editing in PBMCs with PLGA nanoparticle-delivered PNAs confers HIV-1 resistance in humanized mice. Mol Ther Nucleic Acids. 2013;2:e135.
   PubMedGoogle Scholar
• Perumal OP, Inapagolla R, Kannan S, et al. The effect of surface functionality on cellular trafficking of dendrimers. Biomaterials. 2008;29(24–25):3469–3476.
   PubMed Web of Science ®Google Scholar
• Lin Q, Jiang G, Tong K. Dendrimers in drug-delivery applications. Des Monomers Polym. 2010;13(4):301–324.
   Web of Science ®Google Scholar
• Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13(3–4):144–151.
   PubMed Web of Science ®Google Scholar
• Biswas S, Torchilin VP. Dendrimers for siRNA delivery. Pharmaceuticals. 2013;6(2):161–183.
   Google Scholar
• Bauer BJ, Amis EJ. Characterization of dendritically branched polymers by small angle neutron scattering (SANS), small angle X-ray scattering (SAXS) and transmission electron microscopy (TEM) nist.gov. 2001;255–284. https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=853744
   Google Scholar
• Abbasi E, Aval SF, Akbarzadeh A, et al. Dendrimers: synthesis, applications, and properties. Nanoscale Res Lett. 2014;9(1):1–10.
   PubMedGoogle Scholar
• Mintzer MA, Grinstaff MW. Biomedical applications of dendrimers: a tutorial. Chem Soc Rev. 2011;40(1):173–190.
   PubMed Web of Science ®Google Scholar
• Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem. 2010;21(5):797–802.
   PubMed Web of Science ®Google Scholar
• Tomalia DA, Baker H, Dewald J, et al. A new class of polymers: starburst-dendritic macromolecules. Polym J. 1985;17(1):117–132.
   Web of Science ®Google Scholar
• Khan OF, Zaia EW, Yin H, et al. Ionizable amphiphilic dendrimer‐based nanomaterials with alkyl‐chain‐substituted amines for tunable siRNA delivery to the liver endothelium in vivo. Angew Chem. 2014;53(52):14397–14401.
   Google Scholar
• Zhou J, Neff CP, Liu X, et al. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther. 2011;19(12):2228–2238.
   PubMed Web of Science ®Google Scholar
• Rodrigo AC, Rivilla I, Pérez-Martínez FC, et al. Efficient, non-toxic hybrid PPV-PAMAM dendrimer as a gene carrier for neuronal cells. Biomacromolecules. 2011;12(4):1205–1213.
   PubMed Web of Science ®Google Scholar
• Liu X, Li G, Su Z, et al. Poly (amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells. Oncol Rep. 2013;29(4):1387–1394.
   PubMed Web of Science ®Google Scholar
• Dzmitruk V, Apartsin E, Ihnatsyeu-Kachan A, et al. Dendrimers show promise for siRNA and microRNA therapeutics. Pharmaceutics. 2018;10(3):126.
   PubMed Web of Science ®Google Scholar
• Liu X, Rocchi P, Fq Q, et al. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells. ChemMedChem. 2009;4(8):1302–1310.
   PubMed Web of Science ®Google Scholar
• Dong Y, Yu T, Ding L, et al. A dual targeting dendrimer-mediated siRNA delivery system for effective gene silencing in cancer therapy. J Am Chem Soc. 2018;140(47):16264–16274.
   PubMed Web of Science ®Google Scholar
• Ding B-S, Dziubla T, Shuvaev VV, et al. Advanced drug delivery systems that target the vascular endothelium. Mol interv. 2006;6(2):98.
   PubMedGoogle Scholar
• Hua S, Wu SY. The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol. 2013;4:143.
   PubMed Web of Science ®Google Scholar
• Daraee H, Etemadi A, Kouhi M, et al. Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol. 2016;44(1):381–391.
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):1–9.
   PubMedGoogle Scholar
• Simões S, Filipe A, Faneca H, et al. Cationic liposomes for gene delivery. Expert Opin Drug Deliv. 2005;2(2):237–254.
   PubMedGoogle Scholar
• Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014;66:110–116.
   PubMed Web of Science ®Google Scholar
• Yu-Wai-Man C, Tagalakis AD, Manunta MD, et al. Receptor-targeted liposome-peptide-siRNA nanoparticles represent an efficient delivery system for MRTF silencing in conjunctival fibrosis. Sci Rep. 2016;6(1):1–11.
   PubMedGoogle Scholar
• Mokhtarieh AA, Cheong S, Kim S, et al. Asymmetric liposome particles with highly efficient encapsulation of siRNA and without nonspecific cell penetration suitable for target-specific delivery. Biochimi Biophys Acta (BBA) Biomembr. 2012;1818(7):1633–1641.
   PubMed Web of Science ®Google Scholar
• Khabazian E, Vakhshiteh F, Norouzi P, et al. Cationic liposome decorated with cyclic RGD peptide for targeted delivery of anti-STAT3 siRNA to melanoma cancer cells. J Drug Target. 2021;30:522–533. just-accepted.
   Web of Science ®Google Scholar
• Khatoon M, Shah KU, Din FU, et al. Proniosomes derived niosomes: recent advancements in drug delivery and targeting. Drug Deliv. 2017;24(2):56–69.
   PubMed Web of Science ®Google Scholar
• Abdelkader H, Alani AW, Alany RG. Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv. 2014;21(2):87–100.
   PubMed Web of Science ®Google Scholar
• Ag Seleci D, Seleci M, Walter J-G, et al. Niosomes as nanoparticular drug carriers: fundamentals and recent applications. J Nanomater. 2016;2016:1–13.
   Web of Science ®Google Scholar
• Sharma V, Anandhakumar S, Sasidharan M. Self-degrading niosomes for encapsulation of hydrophilic and hydrophobic drugs: an efficient carrier for cancer multi-drug delivery. Mater Sci Eng C. 2015;56:393–400.
   PubMed Web of Science ®Google Scholar
• Ge X, Wei M, He S, et al. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics. 2019;11(2):55.
   PubMed Web of Science ®Google Scholar
• Hemati M, Haghiralsadat F, Yazdian F, et al. Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy. Artif Cells Nanomed Biotechnol. 2019;47(1):1295–1311.
   PubMed Web of Science ®Google Scholar
• Maurer V, Altin S, Ag Seleci D, et al. In-vitro application of magnetic hybrid niosomes: targeted siRNA-delivery for enhanced breast cancer therapy. Pharmaceutics. 2021;13(3):394.
   PubMed Web of Science ®Google Scholar
• Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm. 2008;363(1–2):132–138.
   PubMed Web of Science ®Google Scholar
• Souto E, Müller R. SLN and NLC for topical delivery of ketoconazole. J Microencapsul. 2005;22(5):501–510.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Ray S, Thakur R. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349.
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2012;64:83–101.
   Web of Science ®Google Scholar
• Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289.
   PubMed Web of Science ®Google Scholar
• Dhiman S, Mishra N, Sharma S. Development of PEGylated solid lipid nanoparticles of pentoxifylline for their beneficial pharmacological potential in pathological cardiac hypertrophy. Artif Cells Nanomed Biotechnol. 2016;44(8):1901–1908.
   PubMed Web of Science ®Google Scholar
• Bondì ML, Di Gesù R, Craparo EF. Lipid nanoparticles for drug targeting to the brain. Methods Enzymol. 2012;508:229–251.
   PubMed Web of Science ®Google Scholar
• Mei Z, Chen H, Weng T, et al. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm. 2003;56(2):189–196.
   PubMed Web of Science ®Google Scholar
• Lobovkina T, Jacobson GB, Gonzalez-Gonzalez E, et al. In vivo sustained release of siRNA from solid lipid nanoparticles. ACS nano. 2011;5(12):9977–9983.
   PubMed Web of Science ®Google Scholar
• Oner E, Kotmakci M, Baird A-M, et al. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small‐molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. J Nanobiotechnology. 2021;19(1):1–20.
   PubMed Web of Science ®Google Scholar
• van Vlerken LE, Vyas TK, Amiji MM. Poly (ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res. 2007;24(8):1405–1414.
   PubMed Web of Science ®Google Scholar
• Haggag YA, Faheem AM, Tambuwala MM, et al. Effect of poly (ethylene glycol) content and formulation parameters on particulate properties and intraperitoneal delivery of insulin from PLGA nanoparticles prepared using the double-emulsion evaporation procedure. Pharm Dev Technol. 2018;23(4):370–381.
   PubMed Web of Science ®Google Scholar
• Fonte P, Reis S, Sarmento B. Facts and evidences on the lyophilization of polymeric nanoparticles for drug delivery. J Control Release. 2016;225:75–86.
   PubMed Web of Science ®Google Scholar
• Haggag YA, Matchett KB, Falconer RA, et al. Novel ran-RCC1 inhibitory peptide-loaded nanoparticles have anti-cancer efficacy in vitro and in vivo. Cancers (Basel). 2019;11(2):222.
   PubMed Web of Science ®Google Scholar
• Ibrahim B, Mady OY, Tambuwala MM, et al. pH-Sensitive nanoparticles containing 5-fluorouracil and leucovorin as an improved anti-cancer option for colon cancer. Nanomedicine. 2022;17(6):367–381.
   PubMed Web of Science ®Google Scholar
• Abdelkader DH, Abosalha AK, Khattab MA, et al. A novel sustained anti-inflammatory effect of atorvastatin—calcium PLGA nanoparticles: in vitro optimization and in vivo evaluation. Pharmaceutics. 2021;13(10):1658.
   PubMed Web of Science ®Google Scholar
• Haggag Y, Abu Ras B, El-Tanani Y, et al. Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells. Expert Opin Drug Deliv. 2020;17(11):1655–1669.
   PubMed Web of Science ®Google Scholar
• Luten J, van Nostrum C, De Smedt S, et al. J controlled release: official. J Controlled Release Soc. 2008;126(2):97–110.
   PubMed Web of Science ®Google Scholar
• Gagliardi A, Giuliano E, Eeda V, et al. Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol. 2021;12:17.
   Web of Science ®Google Scholar
• Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011;63(3):170–183.
   PubMed Web of Science ®Google Scholar
• Chereddy KK, Vandermeulen G, Préat V. PLGA based drug delivery systems: promising carriers for wound healing activity. Wound Repair Regener. 2016;24(2):223–236.
   PubMed Web of Science ®Google Scholar
• Lassalle V, Ferreira ML. PLGA based drug delivery systems (DDS) for the sustained release of insulin: insight into the protein/polyester interactions and the insulin release behavior. J Chem Technol Biot. 2010;85(12):1588–1596.
   Web of Science ®Google Scholar
• Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci. 2011;36(7):887–913.
   Web of Science ®Google Scholar
• Pantazis P, Dimas K, Wyche JH, et al. Nanoparticles in Biology and Medicine. In: Preparation of siRNA-encapsulated PLGA nanoparticles for sustained release of siRNA and evaluation of encapsulation efficiency. New York, USA: Springer, 2012; 311–319.
   Google Scholar
• Lee S, Shin H-J, Noh C, et al. IKBKB siRNA-encapsulated poly (lactic-co-glycolic acid) nanoparticles diminish neuropathic pain by inhibiting microglial activation. Int J Mol Sci. 2021;22(11):5657.
   PubMed Web of Science ®Google Scholar
• Pangestuti R, Kim S-K. Neuroprotective properties of chitosan and its derivatives. Mar Drugs. 2010;8(7):2117–2128.
   PubMed Web of Science ®Google Scholar
• Schaly S, Islam P, Abosalha A, et al. Alginate–chitosan hydrogel formulations sustain baculovirus delivery and VEGFA expression which promotes angiogenesis for wound dressing applications. Pharmaceuticals. 2022;15(11):1382.
   Web of Science ®Google Scholar
• Bhumkar DR, Pokharkar VB. Studies on effect of pH on cross-linking of chitosan with sodium tripolyphosphate: a technical note. Aaps Pharmscitech. 2006;7(2):E138–E143.
   PubMed Web of Science ®Google Scholar
• Ragelle H, Riva R, Vandermeulen G, et al. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency. J Control Release. 2014;176:54–63.
   PubMed Web of Science ®Google Scholar
• Li T, Deng N, Xu R, et al. NEAT1 siRNA packed with chitosan nanoparticles regulates the development of colon cancer cells via lncRNA NEAT1/miR-377-3p axis. Biomed Res Int. 2021;2021:5528982.
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541–555.
   PubMed Web of Science ®Google Scholar
• Sokolova V, Epple M. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew Chem. 2008;47(8):1382–1395.
   Google Scholar
• Conde J, Ambrosone A, Hernandez Y, et al. 15 years on siRNA delivery: beyond the state-of-the-art on inorganic nanoparticles for RNAi therapeutics. Nano Today. 2015;10(4):421–450.
   Web of Science ®Google Scholar
• Jiang Y, Huo S, Hardie J, et al. Progress and perspective of inorganic nanoparticle-based siRNA delivery systems. Expert Opin Drug Deliv. 2016;13(4):547–559.
   PubMed Web of Science ®Google Scholar
• Rahme K, Guo J, Holmes JD. Bioconjugated gold nanoparticles enhance siRNA delivery in prostate cancer cells. Rna interference and cancer therapy. New York, USA: Springer; 2019. p. 291–301.
   Google Scholar
• Garrelfs SF, Frishberg Y, Hulton SA, et al., Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021. 384(13): 1216–1226.
   PubMed Web of Science ®Google Scholar
• Chalbatani GM, Dana H, Gharagouzloo E, et al. Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach. Int J Nanomedicine. 2019;14:3111.
   PubMed Web of Science ®Google Scholar
• Bobbin ML, Burnett JC, Rossi JJ. RNA interference approaches for treatment of HIV-1 infection. Genome Med. 2015;7(1):1–16.
   PubMedGoogle Scholar
• Idris A, Davis A, Supramaniam A, et al., A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther. 2021. 29(7): 2219–2226.
   PubMed Web of Science ®Google Scholar